Dr. Lal PathLabs has agreed to buy a 70 percent stake in Gujarat-based SN Genelab for Rs 168 crore, signaling a shift toward high-value genomics. The move aims to move the company away from highly competitive routine diagnostic tests to specialized oncology and rare disease services, potentially protecting profit margins in a crowded sector.
Dr. Lal PathLabs has acquired a 70 percent stake in Gujarat-based SN Genelab Private Ltd for Rs 168 crore. This deal is part of the company's effort to expand its specialized diagnostic services, particularly in genomics, oncology, and rare disease testing. The company intends to integrate these capabilities into its existing national laboratory network.
For many diagnostic chains in India, routine tests like blood sugar or basic blood counts have become a volume-game with thin profit margins due to intense competition from hospital-based labs, large chains, and online diagnostic players. By focusing on specialized genomic testing, Dr. Lal PathLabs is aiming to move up the value chain toward services that are harder to replicate and typically command better pricing power.
The company plans to use its existing network of business-to-business (B2B) and business-to-consumer (B2C) channels to offer these advanced tests to a wider customer base. This is not a standalone move; it follows the recent acquisition of Neuome Technologies in July 2026, showing a clear corporate strategy to shift toward high-end scientific testing. The company is actively investing in sequencing technology to differentiate itself from competitors who rely primarily on standard pathology.
While this expands the firm's technical reach, investors should be aware of the risks involved in such acquisitions. Integrating specialized research firms into a large diagnostics network is operationally complex. There can be execution hurdles, and the initial spending on new technology and lab integration may put pressure on short-term earnings per share. The final benefit will depend on how effectively the company can use its existing distribution network to scale these high-value tests, and whether it can maintain its overall profit margins while managing the rising costs of advanced medical technology.
The next important update for shareholders will be the integration timeline and whether the company can successfully cross-sell these new genomic services across its established centres to justify the investment.